Disclaimer: This report is for informational purposes only. It does not constitute medical advice regarding clinical trials, treatments, or neurodegenerative conditions. Furthermore, it does not serve as personalized financial, legal, or investment advice. Investors should conduct their own due diligence.

MSA: Lundbeck's Game-Changing Data at MDS® 2026!

Executive Summary

Clinical Innovations in MSA: H. Lundbeck A/S presented critical Phase III baseline data for its novel anti-alpha-synuclein monoclonal antibody, amlenetug (Lu AF82422), at the 2026 International Congress of Parkinson's Disease and Movement Disorders (MDS), marking a potential paradigm shift in treating Multiple System Atrophy (MSA). Robust Equity Fundamentals for MSA Safety (NYSE: MSA): Distinct from the medical acronym, MSA Safety Incorporated delivered exceptional Q2 2026 financial results, highlighted by $503.3 million in net sales, a 24% year-over-year increase in adjusted EPS, and surging free cash flow generation. Strategic Expansion via M&A: MSA Safety successfully closed its $555 million acquisition of Norway-based Autronica Fire and Security in July 2026, significantly expanding its fixed gas and fire detection footprint in the maritime and petrochemical sectors while maintaining manageable pro forma leverage. Unwavering Capital Returns: Operating as a prestigious Dividend King, MSA Safety announced its 56th consecutive annual dividend increase in 2026, supported by conservative payout ratios and a newly authorized $500 million share repurchase program.

In addition to the high-level highlights above, this report establishes several concrete baseline metrics central to the dual-MSA narrative. For equity investors assessing MSA Safety Incorporated, the company yields approximately 1.19% to 1.20%, resting on an exceptionally conservative trailing earnings payout ratio of ~26.87%. Following the Autronica acquisition, the company's pro forma net leverage ratio stands at a highly manageable 1.8x, well beneath internal ceilings. The stock trades at a trailing P/E multiple of approximately 22.5x, reflecting a premium earned through consistent free cash flow conversion and high return on equity. The bottom-line investment conclusion suggests MSA Safety remains a premier, defensive mid-cap industrial holding with significant mission-critical market dominance, even amidst temporary inflationary pressures and macroeconomic fluctuations.

This comprehensive research report addresses dual themes surrounding the acronym “MSA” in late 2026. The initial section analyzes the groundbreaking neurodegenerative clinical data for Multiple System Atrophy (MSA) presented by H. Lundbeck A/S at the MDS 2026 Congress, an event that has garnered significant institutional attention. The report then transitions into an exhaustive, fundamental equity deep-dive into MSA Safety Incorporated (NYSE: MSA), a global leader in advanced industrial safety technologies.

For equity investors, the focus remains squarely on MSA Safety's operational resilience, its strategic capital allocation, and its conservative balance sheet. By synthesizing recent SEC filings, investor relations communications, and real-time clinical trial data, this report provides a structured evaluation of dividend sustainability, leverage profiles, valuation metrics, and overarching macroeconomic risks.

Part I: Lundbeck's Clinical Advancements in Multiple System Atrophy (MSA)

The Pathophysiology and Economic Burden of MSA

Multiple System Atrophy (MSA) is a rare, rapidly progressing, and ultimately fatal neurodegenerative disorder. It is characterized by a combination of symptoms that affect both the autonomic nervous system—which controls involuntary functions such as blood pressure and digestion—and movement. The disease shares several physiological similarities with Parkinson's disease, most notably the accumulation of misfolded alpha-synuclein proteins in the brain. However, MSA progresses much faster than Parkinson's disease, and there are currently no approved disease-modifying therapies; existing treatments are entirely symptomatic.

Recent data presented by H. Lundbeck A/S at the International Congress of Parkinson's Disease and Movement Disorders (MDS) in Seoul, South Korea (October 4-8, 2026), has shed new light on the severe healthcare burden associated with the disease. A US observational database study highlighted that patients with MSA incur significantly higher healthcare costs and utilize more healthcare resources compared to patients with Parkinson's disease (PR Newswire). Precise real-time dollar figures are unavailable in the published observational dataset; however, the study confirmed significantly higher healthcare resource utilization across the board, underscoring the intensive care requirements associated with the disease's rapid progression, which generally leads to death within 8.6 years of symptom onset [cite: 1, 2]. This intensive care requirement underscores the urgent unmet medical need and the commercial viability of a disease-modifying therapeutic breakthrough.

Amlenetug (Lu AF82422): Mechanism and MASCOT Phase III Trial

At the core of Lundbeck's presentation at MDS 2026 is amlenetug (formerly Lu AF82422), a human immunoglobulin G1 (IgG1) monoclonal antibody. Amlenetug is engineered to target and bind to all major forms of extracellular alpha-synuclein, with a particularly high affinity for toxic oligomers (small, misfolded clusters of proteins that clump together, damaging brain cells and acting like microscopic pathological debris). By binding to these pathological proteins, the antibody is believed to prevent their cellular uptake, thereby inhibiting the seeding and cell-to-cell spreading of alpha-synuclein aggregation across the brain (MDS Abstracts).

Amlenetug (Lu AF82422) Structured Breakdown

Functional Scope: A human immunoglobulin G1 (IgG1) monoclonal antibody that selectively recognizes and binds to extracellular alpha-synuclein. It addresses the underlying biology of the disease by promoting immune-mediated clearance through microglial Fc receptor engagement [cite: 3]. Cost & Commercial Financials: While exact pricing models for unapproved rare neurodegenerative drugs are heavily guarded, amlenetug is being co-developed under a collaboration between Lundbeck and Genmab. Should it gain approval as a first-in-class treatment, peak sales are projected to command substantial premiums typical for orphan neurological treatments. Genmab and Lundbeck have structured financial obligations wherein Lundbeck bears the majority of royalty payments to earlier developmental partners like Medarex, shielding Genmab's core revenue base [cite: 4]. Availability: Amlenetug is currently restricted to clinical trial environments. It is actively being administered in the global Phase III MASCOT trial (NCT06706622) across North America, Europe, Asia, and Australia as an intravenous infusion once every four weeks [cite: 1]. Real-World Context: The ideal candidate profile involves adults aged 40–75 with a diagnosis of clinically probable or established MSA, showing motor symptoms onset within the past five years. Key contraindications include any prior treatment with other anti-alpha-synuclein therapies or multiple relatives with MSA [cite: 5, 6].

The most anticipated data at MDS 2026 centered on the baseline characteristics of participants enrolled in the MASCOT trial (NCT06706622).

MASCOT Trial Design and Baseline Parameters

| Trial Metric | Specification | | :— | :— | | Trial Name | MASCOT (NCT06706622) | | Phase | Phase III, Global, Randomized, Double-Blind, Placebo-Controlled | | Enrollment | 401 participants across North America, Europe, Asia, and Australia | | Patient Population | Clinically probable or established MSA (both MSA-C and MSA-P subtypes) | | Treatment Duration | 72 weeks (double-blind), followed by an optional open-label extension | | Primary Endpoint Anticipation | Q3 2027 |

The MASCOT trial aims to evaluate the efficacy, safety, and tolerability of intravenous amlenetug administered approximately every four weeks compared to a placebo. The baseline data presented in Seoul confirmed that the trial successfully enrolled a highly diverse and representative cohort, capturing 401 patients with both the cerebellar (MSA-C) and parkinsonian (MSA-P) subtypes of the disease (Fairs Online). Population breakdown aligns with historical prevalence, with approximately two-thirds (66.7%) presenting as the parkinsonian variant (MSA-P), and the remaining one-third as the cerebellar variant (MSA-C) [cite: 2, 7].

The progression of amlenetug into Phase III was heavily supported by the preceding Phase II AMULET trial (NCT05104476), which demonstrated target engagement in both blood plasma and cerebrospinal fluid (CSF), alongside an acceptable safety and tolerability profile.

Specifically, the AMULET trial treated 61 patients (40 on amlenetug, 21 on placebo). While the trial missed its primary endpoint for statistically significant slowing overall (showing a 19% non-significant slowing of clinical progression), a less-impaired subgroup (baseline UMSARS Part I ≤16) demonstrated a promising 37% slowing [cite: 5]. From a safety perspective, 48 of the 61 participants (79%) completed the study, equating to a 21% dropout rate [cite: 8]. Treatment-emergent adverse events (AEs) were near universal (100% in the active group vs 95% in placebo), with severe adverse events (SAEs) occurring at a rate of roughly 30% across both groups (30% amlenetug vs 33% placebo). The most frequent AEs were COVID-19 infection (28%), back pain (15%), headache (13%), urinary tract infection (10%), peripheral edema (10%), flushing (10%), and hypertension (10%) [cite: 8]. Amlenetug is being co-developed under a joint research and licensing agreement between Lundbeck and Genmab A/S, providing a robust developmental backbone for the asset.

Advancements in Diagnostic Tools and Endpoints

Beyond the therapeutic intervention, Lundbeck's MDS 2026 presentations addressed critical structural challenges in executing MSA clinical trials. The company presented extensive validation data for the modified Unified Multiple System Atrophy Rating Scale Part I (mUMSARS Part I)—a scale similar to a 1-10 pain scale, but designed specifically for quantifying the progressive loss of autonomic and motor functions in patients—proposing it as a highly reliable clinical trial endpoint for measuring functional decline. Furthermore, the validation of a Chinese-language version of the UMSARS and new research into CSF biomarkers signify a comprehensive approach to disease detection, differential diagnosis, and long-term monitoring (MarketScreener).

In tandem with its MSA data, Lundbeck also presented Phase Ib findings for Lu AF28996, a novel oral D1-like/D2-like dopamine receptor agonist (a compound designed to mimic the brain's natural dopamine to stimulate specific receptors, effectively bypassing damaged neurons to restore motor control). This therapy is intended for patients with advanced Parkinson's disease experiencing difficult-to-control motor fluctuations. The combination of amlenetug and Lu AF28996 cements Lundbeck's position as a premier innovator in the movement disorder space, setting the stage for major commercial catalysts in 2027 when the MASCOT Phase III results are formally unblinded.

Part II: Equity Deep Dive – MSA Safety Incorporated (NYSE: MSA)

Transitioning from clinical data to industrial equities, MSA Safety Incorporated (NYSE: MSA) represents a foundational pillar in the global safety equipment market. Founded in 1914 and headquartered in Cranberry Township, Pennsylvania, the company develops, manufactures, and sells advanced safety products designed to protect workers and facility infrastructure in highly hazardous environments.

Q2 2026 Financial and Operational Overview

MSA Safety delivered a resounding financial performance in the second quarter of 2026, characterized by robust top-line growth, significant margin expansion, and accelerated free cash flow generation. The company's mission-critical product portfolio—which spans fixed and portable gas detection systems, industrial head protection, fall protection, and self-contained breathing apparatuses (SCBAs) for the fire service—provides a durable competitive moat against macroeconomic volatility.

Earnings Meat: Q2 2026 Financial Highlights

| Financial Metric | Q2 2026 Result | Year-Over-Year Growth / Change | | :— | :— | :— | | Net Sales (GAAP) | $503.3 million | +6.2% | | Organic Sales Growth | N/A | +3.0% | | GAAP Operating Margin | 22.2% | +410 basis points | | Adjusted Operating Margin | 24.1% | +270 basis points | | GAAP Net Income | $86.2 million | +37.0% | | GAAP Diluted EPS | $2.23 | +40.0% | | Adjusted Diluted EPS | $2.40 | +24.0% | | Free Cash Flow | $82.7 million | +118.0% |

The underlying mechanics of this financial outperformance reveal a company successfully navigating a complex global supply chain while exercising immense pricing power. The 270 basis-point expansion in adjusted operating margin to 24.1% was primarily driven by strategic price adjustments, internal productivity gains, and a one-time tariff-related refund (Seeking Alpha).

Regionally, the Americas segment remained the dominant growth engine, recording a 6.7% increase in net sales to $341.4 million. Organic sales in the Americas grew by 4.5%, driven by distinct strengths: the segment delivered double-digit organic growth specifically in industrial personal protective equipment (PPE) and high single-digit organic growth in detection solutions [cite: 9]. The introduction and adoption of the V-Gard H2® Full Brim Safety Helmet and the continued rollout of MSA+ connected software subscriptions have created a high-margin, recurring revenue tailwind that insulates the company from cyclical hardware downturns (Clear Thesis).

Conversely, the International segment presented a mixed narrative. While overall international sales increased by 5.1% year-over-year to $161.9 million [cite: 9], organic sales in the international fixed detection segment sank by 13%. Management explicitly attributed this decline to the ongoing geopolitical conflict in the Middle East, which delayed fixed-monitoring demand and shipment activities. According to executive commentary during the earnings call, the Middle East friction negatively impacted first-half results by approximately 1.5% (Seeking Alpha News). Despite these volume headwinds, the international division managed to increase its adjusted operating profit by 24% to $25.1 million, showcasing rigorous cost control and favorable product mix management.

In the Fire Service segment, net sales experienced a marginal 2% year-over-year decline in Q2 2026. This softness is primarily structural rather than competitive. Orders reliant on the US federal Assistance to Firefighters Grant (AFG) program materialized slower than initially modeled. Furthermore, the natural replacement cycle for breathing apparatuses is not projected to reach its next major inflection point until 2027 (Lightyear). However, management noted an acceleration in orders during June and July, suggesting that the trough in fire service demand may have already passed.

The Autronica Fire and Security Acquisition & TAM Expansion

In a definitive move to consolidate its market leadership in fixed detection, MSA Safety completed the acquisition of Norway-based Autronica Fire and Security on July 9, 2026. Valued at approximately $555 million, the transaction was financed using a combination of cash on hand and borrowings under MSA's existing senior revolving credit facility (TradingView).

Autronica, a highly specialized provider of regulatory-certified marine fire detection, gas detection, and alarm systems, reported approximately $160 million in sales in 2025. The strategic rationale behind this acquisition is multifaceted. First, it significantly deepens MSA's penetration into harsh-environment end markets, specifically the global maritime, energy, and petrochemical sectors. Second, it expands MSA's total addressable market (TAM) in fixed fire and gas detection to over $3 billion.

To capture this expanded $3 billion TAM, MSA must directly compete with established mega-cap safety conglomerates such as Honeywell International Inc. and 3M Company, as well as niche specialists like Drägerwerk [cite: 10, 11]. MSA's primary competitive advantage against these larger, heavily diversified incumbents relies on its pure-play safety focus. While 3M and Honeywell operate vast portfolios spanning diverse industrial sectors, MSA's specialized mission-critical focus, aggressive investment into smart helmet capabilities (like the V-Gard series), and the integration of the proprietary MSA+ software ecosystem provide a deeper, more tailored offering for enterprise safety professionals [cite: 10].

Financially, the deal is constructed to generate immediate value. Management projects that the Autronica acquisition will be accretive to MSA Safety's adjusted earnings per share within the first full year of ownership. By integrating Autronica's installed base with MSA's connected safety ecosystem, cross-selling opportunities are expected to drive top-line synergies, while operational integration should yield standard back-office cost efficiencies (Simply Wall St).

However, the acquisition is not without integration risks. Autronica operates extensively across international markets and reports in foreign currencies, increasing MSA's exposure to foreign exchange volatility. The integration of global supply chains, particularly amidst ongoing logistical constraints in Europe and the Middle East, will require tight operational oversight to prevent margin dilution in the near term.

Dividend Policy, History, and Yield Analysis

For income-focused equity investors, MSA Safety is a paragon of capital return reliability. The company is a certified “Dividend King,” a prestigious designation reserved for companies that have increased their annual dividend payouts for 50 or more consecutive years.

The Meat: Dividend Metrics and Yield Configuration

| Dividend Metric | Current Status (As of Q3 2026) | | :— | :— | | Consecutive Years of Dividend Increases | 56 Years | | Quarterly Dividend per Share | $0.54 | | Annualized Dividend per Share | $2.16 | | Trailing Dividend Yield | ~1.19% – 1.20% | | Earnings Payout Ratio (TTM) | 26.39% – 26.87% | | Cash Flow Payout Ratio | ~22.24% – 24.00% | | 5-Year Average Annual Dividend Growth | ~4.25% – 5.40% |

In May 2026, the Board of Directors authorized the company's 56th consecutive annual dividend increase, raising the quarterly payout from $0.53 to $0.54 per share. While the absolute yield of approximately 1.20% is modest and slightly trails the highest quartile of American dividend payers (which average above 4%), the safety and sustainability of this distribution are nearly unimpeachable (Stock Analysis).

The synthesis of this dividend profile reveals extreme conservatism in capital management. The company currently pays out only 26.87% of its trailing earnings and an even lower 22.24% of its free cash flow as dividends (MarketBeat). This exceptionally low payout ratio serves a dual purpose: it virtually eliminates the risk of a dividend cut during severe macroeconomic downturns, and it allows the company to retain vast amounts of internal capital to fund strategic acquisitions (such as Autronica) and aggressive share repurchases.

Complementing the dividend policy, the MSA Board of Directors authorized a new $500 million share repurchase program in February 2026, replacing a previous $200 million authorization (PR Newswire). During the first half of 2026, MSA aggressively executed against this authorization, returning a total of $118 million to shareholders via combined buybacks and dividends—a 45% increase compared to the first half of 2025. However, in light of the debt undertaken to acquire Autronica, management clearly signaled during the Q2 2026 earnings call that the pace of share repurchases will slow in the second half of 2026 as free cash flow is redirected toward rapid debt amortization (Motley Fool Transcripts).

Capital Structure, Leverage, and Maturities

A critical component of MSA Safety's equity thesis is its historically pristine balance sheet, which provided the exact financial flexibility necessary to execute the Autronica acquisition without jeopardizing its investment-grade credit profile.

At the close of Q2 2026 (June 30, prior to the final cash outlay for Autronica), MSA reported a highly conservative net leverage ratio of just 0.8x (net debt to adjusted EBITDA). Total end-of-period debt stood at $599.7 million, offset by a robust $200.1 million in cash and cash equivalents.

Debt Maturity Profile (SEC Form 10-Q disclosures as of mid-2026)

| Debt Instrument | Outstanding Balance (Net of Costs) | Maturity Date | Interest Structure | | :— | :— | :— | :— | | Senior Revolving Credit Facility | $309.8 million | 2030 | Variable (Base Rate / SOFR + Margin) | | 2023 Senior Notes | $50.0 million | 2028 | Fixed at 5.25% | | Total Long-Term Debt | ~$591.6 million | | | | Current Portion (Due within 1 yr) | ~$8.1 million | | |

Note: The balances above reflect the Q2 2026 SEC 10-Q filing prior to the July finalization of the Autronica acquisition debt draw. (SEC.gov)

When adjusting for the Autronica acquisition—which was financed using cash on hand and a draw against the revolving credit facility—MSA's pro forma net leverage ratio rose to approximately 1.8x as of June 30, 2026. This metric actually came in 0.2x lower than management's initial projections during the deal announcement, underscoring the company's stronger-than-expected cash generation in Q2 (StockTitan).

A pro forma leverage ratio of 1.8x remains comfortably below management's internal threshold of 2.0x and is highly manageable given the company's free cash flow conversion rate of 96%. Interest coverage remains exceptionally strong at approximately 13.3x to 15x. However, the reliance on a variable-rate revolving credit facility for the Autronica purchase does introduce moderate interest rate sensitivity, governed by SOFR (the Secured Overnight Financing Rate—a benchmark interest rate that dictates the cost of borrowing; as it fluctuates, so does the interest expense on MSA's variable debt). Management updated its full-year 2026 interest expense guidance to a range of $40 million to $43 million, reflecting the higher debt load and prevailing SOFR rates. The stated corporate priority for the second half of 2026 is swift debt repayment to rebuild balance sheet capacity for future M&A activities, a strategy supported by pro forma post-acquisition liquidity of $600 million.

Valuation and Market Performance

MSA Safety trades at a premium multiple relative to broader industrial peers, a valuation justified by its mission-critical product suite, high switching costs, and non-cyclical end markets. Despite a lower dividend yield than its conglomerate peers, MSA's premium Price-to-Earnings multiple reflects its specialized market dominance and highly resilient ROE.

| Company | Ticker | Trailing P/E | Forward P/E | Return on Equity (ROE) | Dividend Yield | | :— | :— | :— | :— | :— | :— | | MSA Safety | MSA | 22.5x | ~19.3x | >20.0% | ~1.20% | | Honeywell | HON | 7.9x | 21.2x | 40.37% | 3.68% – 4.60% | | 3M Company | MMM | 30.0x | 28.9x | 77.92% | 1.79% – 1.86% | | Drägerwerk | 0MT8 | 14.0x (2026E) | N/A | 10.9% | 2.50% |

Based on trailing twelve-month (TTM) earnings of $8.04 per share, the stock trades at a Price-to-Earnings (P/E) ratio of approximately 22.5x. Analysts forecast forward earnings to grow by over 9% to $9.96 per share in 2027, yielding a forward P/E in the high teens (MarketBeat). This multiple is actually slightly below the company's historical five-year average, suggesting modest relative undervaluation despite the stock's recent technical breakout.

Following the Q2 2026 earnings release and the closure of the Autronica deal, MSA shares experienced a decisive upside breakout, jumping from consolidation in the $170s to highs near $193. The underlying return metrics validate this price action: MSA generates a Return on Equity (ROE) exceeding 20% and a Return on Invested Capital (ROIC) of approximately 16% (StocksToTrade). These returns are exceptionally high for a mid-cap industrial manufacturer and indicate a wide economic moat, driven largely by regulatory compliance requirements and the high cost of failure associated with industrial safety equipment. Competitor substitution is highly unlikely when human lives and multi-billion-dollar facility infrastructures are reliant on proven, certified technologies.

Risks, Red Flags, and Open Questions

While the fundamental narrative for MSA Safety is highly constructive, several macroeconomic and operational risks warrant close monitoring by equity analysts:

1. Interest Rate Pressures on Municipal Budgets: The US Federal Reserve's maintenance of a “higher for longer” interest rate environment poses a downstream risk to MSA's Fire Service segment. With 30-year Treasury yields crossing 5.25% in late 2026, borrowing costs for municipalities have surged. Squeezed municipal budgets could delay the multi-year replacement cycles for essential firefighting gear and breathing apparatuses (Clear Thesis). The reliance on federal AFG funding introduces political and administrative lumpiness into MSA's revenue stream, as evidenced by the 2% YoY decline in Fire Service sales in Q2 2026.

2. Geopolitical Friction and Supply Chain Inflation: As noted in the Q2 earnings, the ongoing conflict in the Middle East has already shaved an estimated 1.5% off MSA's first-half results due to delayed shipments of fixed monitoring equipment. Furthermore, management has warned that higher input costs related to raw materials are presenting margin pressures. Specifically, MSA heavily relies on high-density polyethylene (HDPE) and polycarbonate resins, as well as specialized metals, to manufacture their hard hats and detection shells. Because these resins are petroleum-derived, they leave MSA highly sensitive to global oil price fluctuations and broader commodity inflation if long-term price-lock strategies fail [cite: 10, 12]. Consequently, full-year adjusted gross margin guidance has been conservatively pegged at 47.5% to 48.5%, anticipating these exact inflationary headwinds.

3. Energy Sector Capital Expenditure (CapEx): A significant portion of MSA's detection equipment (and notably, Autronica's newly acquired maritime/petrochemical portfolio) is highly dependent on capital expenditures in the global oil and gas sector. Projections from industry analysts (such as Baker Hughes) suggest a modest decline in global oil and gas producer spending through late 2026 and 2027. If energy producers curtail facility upgrades in response to volatile crude pricing, MSA's high-margin detection segment could face demand compression.

4. Autronica Integration Execution: While strategically sound, integrating a $555 million international entity requires substantial management bandwidth. The expected accretion to EPS is contingent upon seamless technological integration into the MSA+ software ecosystem and the successful navigation of foreign exchange translational risks between the Norwegian Krone, the Euro, and the US Dollar.

Synthesis and Conclusion

The convergence of the “MSA” acronym in 2026 highlights two distinct but equally compelling narratives of resilience and innovation. In the biotechnology sphere, Lundbeck's MDS 2026 presentation of the Phase III MASCOT baseline data for amlenetug represents a beacon of hope for combatting Multiple System Atrophy (MSA). The meticulous trial design and target engagement data suggest that the industry is inching closer to a disease-modifying breakthrough for a devastating condition.

Concurrently, on the industrial equity front, MSA Safety Incorporated (NYSE: MSA) operates from a position of absolute financial strength. The Q2 2026 financial results demonstrate a company that is masterfully utilizing pricing power and operational efficiency to expand margins in a complex macro environment. The acquisition of Autronica represents a calculated, highly synergistic deployment of capital that expands the company's total addressable market while maintaining a secure, investment-grade leverage profile of 1.8x.

Fortified by its status as a 56-year Dividend King, a conservative sub-30% payout ratio, and prolific free cash flow generation, MSA Safety remains a premier equity holding for investors seeking downside protection, reliable income growth, and mission-critical market dominance in the industrial safety sector.

Sources: 1. marketscreener.com 2. prnewswire.com 3. delveinsight.com 4. genmab.com 5. neurologylive.com 6. anzctr.org.au 7. delveinsight.com 8. neurologylive.com 9. sec.gov 10. dataintelo.com 11. fairvalue-calculator.com 12. sec.gov

For informational purposes only; not investment advice.